Literature DB >> 11264249

Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes.

A A Parsons1, S Bingham, P Raval, S Read, M Thompson, N Upton.   

Abstract

1. The effects of tonabersat (SB-220453) were evaluated on trigeminal nerve ganglion stimulation-induced sensory-autonomic neurovascular reflexes in the anaesthetized cat. Comparisons were made to intravenous administration of carabersat (SB-204269), and to valproate, gabapentin and lamotrigine following intraduodenal administration. 2. There were no effects on resting blood pressure, heart rate, carotid blood flow or carotid vascular resistance for any compound evaluated. 3. Trigeminal nerve ganglion stimulation increased carotid blood flow by 65% and reduced vascular resistance by 41% with minimal effect on blood pressure (< 10%) and no effect on heart rate. Intravenous infusion of tonabersat or carabersat (both 3.4 micromol h(-1)) produced time related reductions in stimulation-induced responses with a maximal inhibition (relative to control) of 30 +/- 7% (n=4), at 240 min for tonabersat and 33+/-4% (n=3) at 180 min for carabersat. Tonabersat (11.5 micromol h(-1)) produced a similar inhibitory effect (32 +/- 9%, n=4) after 120 min of infusion. 4. Following intraduodenal administration of tonabersat, the maximal inhibition of nerve stimulation-induced responses was 55 +/- 4% at 120 min (n=4) for tonabersat 10 mg kg(-1), and 24+/-2% after 180 min for 1 mg kg(-1) (n=4). 5. Intraduodenal administration of sodium valproate (10 or 100 mg kg(-1) n=4/group) had no effect on neurovascular reflexes. Maximal inhibition of nerve ganglion-stimulated reductions in carotid vascular resistance were observed at 150 min for lamotrigine (50 mg kg(-1), 52+/-12%, n=4) and gabapentin (100 mg kg(-1), 17+/-13%, n=3). Lamotrigine 10 mg kg(-1) produced 22+/-11% (n=3) inhibition after 180 min. 6. These data demonstrate blockade of trigeminal parasympathetic reflexes with tonabersat, carabersat and other anticonvulsants. These agents may therefore have therapeutic benefit in conditions where this type of reflex is evident.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264249      PMCID: PMC1572685          DOI: 10.1038/sj.bjp.0703932

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

Review 1.  Benzo[b]pyranols and related novel antiepileptic agents.

Authors:  N Upton; M Thompson
Journal:  Prog Med Chem       Date:  2000

2.  SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat.

Authors:  S J Read; M I Smith; A J Hunter; N Upton; A A Parsons
Journal:  Cephalalgia       Date:  2000-03       Impact factor: 6.292

3.  Intranasal lidocaine to prevent headache following migraine aura.

Authors:  M Maizels
Journal:  Headache       Date:  1999-06       Impact factor: 5.887

Review 4.  Nonepileptic uses of gabapentin.

Authors:  L Magnus
Journal:  Epilepsia       Date:  1999       Impact factor: 5.864

5.  Decreased carotid arterial resistance in cats in response to trigeminal stimulation.

Authors:  G A Lambert; N Bogduk; P J Goadsby; J W Duckworth; J W Lance
Journal:  J Neurosurg       Date:  1984-08       Impact factor: 5.115

6.  Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90.

Authors:  P J Goadsby; L Edvinsson
Journal:  Headache       Date:  1994 Jul-Aug       Impact factor: 5.887

7.  Investigation of the role of tachykinin NK1, NK2 receptors and CGRP receptors in neurogenic plasma protein extravasation in dura mater.

Authors:  C T O'Shaughnessy; H E Connor
Journal:  Eur J Pharmacol       Date:  1994-09-22       Impact factor: 4.432

8.  Neuropeptides in the cerebral circulation: relevance to headache.

Authors:  L Edvinsson; P J Goadsby
Journal:  Cephalalgia       Date:  1995       Impact factor: 6.292

9.  Simultaneous measurement of plasma protein extravasation and carotid vascular resistance in the rat.

Authors:  R A Spokes; V C Middlefell
Journal:  Eur J Pharmacol       Date:  1995-07-25       Impact factor: 4.432

10.  Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide.

Authors:  K J Escott; D T Beattie; H E Connor; S D Brain
Journal:  Brain Res       Date:  1995-01-09       Impact factor: 3.252

View more
  10 in total

Review 1.  Prophylactic migraine therapy: emerging treatment options.

Authors:  Marcelo E Bigal; Abouch V Krymchantowski; Alan M Rapoport
Journal:  Curr Pain Headache Rep       Date:  2004-06

Review 2.  Molecular targets for antiepileptic drug development.

Authors:  Brian S Meldrum; Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

3.  Pharmacology.

Authors:  Hayrunnisa Bolay; Paul Durham
Journal:  Handb Clin Neurol       Date:  2010

4.  Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels.

Authors:  Yeri Kim; Jarred M Griffin; Mohd N Mat Nor; Jie Zhang; Peter S Freestone; Helen V Danesh-Meyer; Ilva D Rupenthal; Monica Acosta; Louise F B Nicholson; Simon J O'Carroll; Colin R Green
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

5.  Tonabersat inhibits trigeminal ganglion neuronal-satellite glial cell signaling.

Authors:  Srikanth Damodaram; Srikanth Thalakoti; Stacy E Freeman; Filip G Garrett; Paul L Durham
Journal:  Headache       Date:  2009-01       Impact factor: 5.887

Review 6.  Neurological mechanisms of migraine: potential of the gap-junction modulator tonabersat in prevention of migraine.

Authors:  P L Durham; F G Garrett
Journal:  Cephalalgia       Date:  2009-11       Impact factor: 6.292

Review 7.  Involvement of gap junction channels in the pathophysiology of migraine with aura.

Authors:  Denis Sarrouilhe; Catherine Dejean; Marc Mesnil
Journal:  Front Physiol       Date:  2014-02-25       Impact factor: 4.566

Review 8.  Influence of drugs on gap junctions in glioma cell lines and primary astrocytes in vitro.

Authors:  Zahra Moinfar; Hannes Dambach; Pedro M Faustmann
Journal:  Front Physiol       Date:  2014-05-16       Impact factor: 4.566

9.  Inhibition of gap junctional intercellular communication by an anti-migraine agent, flunarizine.

Authors:  Joo Hye Yeo; Eun Ju Choi; Jinu Lee
Journal:  PLoS One       Date:  2019-09-12       Impact factor: 3.240

Review 10.  New drugs for migraine.

Authors:  Lars Jacob Stovner; Erling Tronvik; Knut Hagen
Journal:  J Headache Pain       Date:  2009-10-01       Impact factor: 7.277

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.